clovis oncology a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the united states, europe and additional international markets. the company's development programs are targeted at specific subsets of the cancer population, combining personalized medicine with companion diagnostics to direct products to those patients most likely to benefit from their use. we have three product candidates in clinical development: rociletinib (co-1686), which is in development for the treatment of non-small cell lung cancer; rucaparib, in development for the treatment of ovarian cancer and other solid tumors; and lucitanib, which is in development for the treatment of breast cancer and other solid tumors. we maintain global rights for rociletinib and rucaparib, and u.s. and japanese rights to lucitanib.
Company profile
Ticker
CLVSQ
Exchange
Website
CEO
Patrick Mahaffy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Clovis Oncology UK Limited • Clovis Oncology IT Srl • Clovis Oncology Switzerland GmbH • Clovis Oncology France SAS • Clovis Oncology Germany GmbH • Clovis Oncology Denmark ApS • Clovis Oncology Ireland Limited ...
IRS number
900475355
CLVSQ stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
18 Jul 23
15-12G
Securities registration termination
11 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jul 23
Transcripts
CLVSQ
Earnings call transcript
2022 Q2
8 Aug 22
CLVSQ
Earnings call transcript
2022 Q1
4 May 22
CLVSQ
Earnings call transcript
2021 Q4
23 Feb 22
CLVSQ
Earnings call transcript
2021 Q3
3 Nov 21
CLVSQ
Earnings call transcript
2021 Q2
5 Aug 21
CLVSQ
Earnings call transcript
2021 Q1
5 May 21
CLVSQ
Earnings call transcript
2020 Q4
23 Feb 21
CLVSQ
Earnings call transcript
2020 Q3
5 Nov 20
CLVSQ
Earnings call transcript
2020 Q2
6 Aug 20
CLVSQ
Earnings call transcript
2020 Q1
5 May 20
Latest ownership filings
SC 13G/A
HIGHBRIDGE CAPITAL MANAGEMENT LLC
10 Feb 23
4
Paul Edward Gross
3 Nov 22
4
GILLIAN C IVERS-READ
3 Nov 22
4
Thomas C. Harding
3 Nov 22
4
DANIEL W MUEHL
3 Nov 22
4
Lindsey Rolfe
3 Nov 22
4
Thomas C. Harding
4 Oct 22
4
Lindsey Rolfe
6 Sep 22
4
Paul Edward Gross
6 Sep 22
4
Thomas C. Harding
6 Sep 22
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 58.32 mm | 58.32 mm | 58.32 mm | 58.32 mm | 58.32 mm | 58.32 mm |
Cash burn (monthly) | 12.09 mm | 9.47 mm | 18.66 mm | 21.03 mm | 13.54 mm | 14.63 mm |
Cash used (since last report) | 225.57 mm | 176.72 mm | 348.25 mm | 392.41 mm | 252.64 mm | 273.07 mm |
Cash remaining | -167.25 mm | -118.40 mm | -289.93 mm | -334.09 mm | -194.32 mm | -214.75 mm |
Runway (months of cash) | -13.8 | -12.5 | -15.5 | -15.9 | -14.4 | -14.7 |
Institutional ownership, Q4 2020
11.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 4 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 82.47 mm |
Total shares | 17.18 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Highbridge Capital Management | 9.91 mm | $47.56 mm |
Palo Alto Investors | 4.47 mm | $21.45 mm |
Citadel Advisors | 1.53 mm | $7.34 mm |
Whitebox Advisors | 1.28 mm | $6.13 mm |
Capital World Investors | 0.00 | $0.00 |
Redmile | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Nov 22 | Paul Edward Gross | Common Stock | Sell | Dispose S | No | No | 0.9829 | 2,135 | 2.10 k | 98,330 |
2 Nov 22 | Paul Edward Gross | Common Stock | Sell | Dispose S | No | No | 0.9829 | 2,595 | 2.55 k | 95,840 |
2 Nov 22 | Gillian C Ivers-read | Common Stock | Sell | Dispose S | No | No | 0.9829 | 2,006 | 1.97 k | 293,612 |
2 Nov 22 | Gillian C Ivers-read | Common Stock | Sell | Dispose S | No | No | 0.9829 | 1,675 | 1.65 k | 290,993 |
2 Nov 22 | Thomas C. Harding | Common Stock | Sell | Dispose S | Yes | No | 0.9827 | 63 | 61.91 | 3,801 |
2 Nov 22 | Thomas C. Harding | Common Stock | Sell | Dispose S | No | No | 0.9829 | 915 | 899.35 | 19,487 |
2 Nov 22 | Thomas C. Harding | Common Stock | Sell | Dispose S | No | No | 0.9829 | 788 | 774.53 | 18,590 |
2 Nov 22 | Daniel W Muehl | Common Stock | Sell | Dispose S | No | No | 0.983 | 2,066 | 2.03 k | 104,830 |
2 Nov 22 | Daniel W Muehl | Common Stock | Sell | Dispose S | No | No | 0.983 | 2,513 | 2.47 k | 102,271 |
2 Nov 22 | Lindsey Rolfe | Common Stock | Sell | Dispose S | No | No | 0.9829 | 2,353 | 2.31 k | 113,691 |